©The Author(s) 2026.
World J Transplant. Mar 18, 2026; 16(1): 114367
Published online Mar 18, 2026. doi: 10.5500/wjt.v16.i1.114367
Published online Mar 18, 2026. doi: 10.5500/wjt.v16.i1.114367
Figure 2 Distribution of induction therapy practices among kidney transplant centers in India.
A-D: Survey responses to the query regarding the most common (A), second most common (B), third most common (C), and least common (D) induction therapies used by kidney transplant centers across India. ATG: Anti-thymocyte globulin; IL-2RA: Interleukin-2 receptor antagonist; ATLG: Anti-T-lymphocyte globulin.
- Citation: Kute VB, Balwani MR, Shrimali JB, Pasari A, Kher V, Patel MP, Chafekar D, Guditi S, Das P, Siddaiah GM, Godara SM, Bhargava V, Gupta A, Ramteke V, Deshpande N, Tolani P, Prasad N, Patil RK, Mohanka R, Mahajan S, Sharma S, Banerjee S, Engineer DP, Agarwal D, Kashiv P, Lahiri A, Khullar D, Srivastava A. Induction therapy in kidney transplant recipients: A consensus statement of Indian Society of Organ Transplantation. World J Transplant 2026; 16(1): 114367
- URL: https://www.wjgnet.com/2220-3230/full/v16/i1/114367.htm
- DOI: https://dx.doi.org/10.5500/wjt.v16.i1.114367